Immunological checkpoint inhibitors enter adolescence
- PMID: 24035406
- DOI: 10.1016/S1470-2045(13)70401-7
Immunological checkpoint inhibitors enter adolescence
Comment on
-
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11. Lancet Oncol. 2013. PMID: 24035405 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
